{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:33:04Z","timestamp":1790616784269,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-018-3666-8","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T12:02:23Z","timestamp":1547726543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice"],"prefix":"10.1186","volume":"19","author":[{"given":"Alberto","family":"Borghetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Gagliardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmaria","family":"Baldin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Ciccullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Moschese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Emiliozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Belmonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lamonica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Montagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Giambenedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"issue":"1","key":"3666_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","volume":"85","author":"S Broder","year":"2010","unstructured":"Broder S. The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic. Antivir Res. 2010;85(1):1\u201318.","journal-title":"Antivir Res"},{"key":"3666_CR2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. . (Updated 17 October 2017. Accessed on 22 Aug 2017). Available at \n                    http:\/\/www.aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf\n                    \n                  ."},{"key":"3666_CR3","unstructured":"EACS Guidelines version 8.2, January 2017. Available at \n                    http:\/\/www.eacsociety.org\/files\/guidelines_9.0-english.pdf\n                    \n                  ."},{"issue":"9","key":"3666_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fatkenheuer G, Llibre JM, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807.","journal-title":"N Engl J Med"},{"key":"3666_CR5","unstructured":"Smit M, Cassidy R, Cozzi-Lepri A, et al. Quantifying the future clinical burden of an ageing HIV positive population in Italy. a mathematical modelling study. HIV Drug Therapy. 23\u201326 October 2016, Glasgow, UK. Abstract P156."},{"issue":"1","key":"3666_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","volume":"10","author":"AM Margolis","year":"2014","unstructured":"Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10(1):26\u201339.","journal-title":"J Med Toxicol"},{"key":"3666_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-014-0142-1","volume":"12","author":"N Langebeek","year":"2014","unstructured":"Langebeek N, Gisolf EH, Reiss P, Vervoort SC, Hafsteinsdottir TB, Richter C, Sprangers MA, Nieuwkerk PT. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014;12:142.","journal-title":"BMC Med"},{"issue":"4","key":"3666_CR8","doi-asserted-by":"publisher","first-page":"e0125018","DOI":"10.1371\/journal.pone.0125018","volume":"10","author":"F Nakagawa","year":"2015","unstructured":"Nakagawa F, Miners A, Smith CJ, Simmons R, Lodwick RK, Cambiano V, Lundgren JD, Delpech V, Phillips AN. Projected lifetime healthcare costs associated with HIV infection. PLoS One. 2015;10(4):e0125018.","journal-title":"PLoS One"},{"issue":"7","key":"3666_CR9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(15)00096-1","volume":"15","author":"JR Arribas","year":"2015","unstructured":"Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martinez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. Lancet Infect Dis. 2015;15(7):785\u201392.","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"3666_CR10","first-page":"1163","volume":"72","author":"S Giambenedetto Di","year":"2017","unstructured":"Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, et al. Treatment simplification to atazanavir\/ritonavir + lamivudine versus maintenance of atazanavir\/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017;72(4):1163\u201371.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"3666_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jinf.2016.08.011","volume":"73","author":"M Fabbiani","year":"2016","unstructured":"Fabbiani M, Di Giambenedetto S, Poli A, Borghetti A, Castagna A, Mondi A, Galizzi N, Maillard M, Gori A, Cauda R, et al. Simplification to a dual regimen with darunavir\/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. J Infect. 2016;73(6):619\u201323.","journal-title":"J Infect"},{"issue":"1","key":"3666_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1093\/jac\/dkw379","volume":"72","author":"JA Perez-Molina","year":"2017","unstructured":"Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suarez-Lozano I, Riera M, Estebanez M, Palacios R, Sanz-Moreno J, Troya J, et al. Simplification to dual therapy (atazanavir\/ritonavir + lamivudine) versus standard triple therapy [atazanavir\/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study). J Antimicrob Chemother. 2017;72(1):246\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"3666_CR13","doi-asserted-by":"crossref","unstructured":"Pulido F, Ribera E, Lagarde M, Perez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, et al. Dual therapy with darunavir and ritonavir plus lamivudine versus triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of HIV-1 viral suppression: randomised, open label, non-inferiority DUAL-GESIDA 8014-RIS-EST45 trial. Clin Infect Dis. 2017;65(12):2112\u201318.","DOI":"10.1093\/cid\/cix734"},{"issue":"7","key":"3666_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/jac\/dkw032","volume":"71","author":"C Marzolini","year":"2016","unstructured":"Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016;71(7):1755\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"3666_CR15","unstructured":"Joly V, Burdet C, Landman R, et al. Promising results of dolutegravir + lamivudine maintenance in ANRS 167 LAMIDOL Trial. 24th Conference on Retroviruses and Opportunistic Infections. 13\u201316 February 2017, Seattle, WA, USA. Abstract 458."},{"issue":"5","key":"3666_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40265-016-0553-8","volume":"76","author":"SG Kelly","year":"2016","unstructured":"Kelly SG, Nyaku AN, Taiwo BO. Two-drug treatment approaches in HIV: finally getting somewhere? Drugs. 2016;76(5):523\u201331.","journal-title":"Drugs"},{"issue":"1","key":"3666_CR17","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12879-017-2311-2","volume":"17","author":"F Maggiolo","year":"2017","unstructured":"Maggiolo F, Gulminetti R, Pagnucco L, Digaetano M, Benatti S, Valenti D, Callegaro A, Ripamonti D, Mussini C. Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients. BMC Infect Dis. 2017;17(1):215.","journal-title":"BMC Infect Dis"},{"key":"3666_CR18","unstructured":"Reynes J, Meftah N, Tuaillon E, et al. Dual regimen with Dolutegravir and Lamivudine maintains virologic suppression even in heavily treatment experienced HIV-infected patients: 96 weeks results from maintenance DOLULAM study. 9th IAS Conference on HIV Science. 23\u201326 July 2017, Paris, France. Abstract MOPEB0322. ."},{"key":"3666_CR19","unstructured":"Cahn P, Rol\u00f2n MJ, Figueroa MI, et al. Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV naive patients: 48 week results of the PADDLE trial. 21st International AIDS Conference. 18\u201322 July 2016, Durban, South Africa. Abstract FRAB0104LB."},{"issue":"15","key":"3666_CR20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1097\/QAD.0000000000001191","volume":"30","author":"M Oliveira","year":"2016","unstructured":"Oliveira M, Ibanescu RI, Pham HT, Brenner B, Mesplede T, Wainberg MA. The M184I\/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir. AIDS. 2016;30(15):2267\u201373.","journal-title":"AIDS"},{"key":"3666_CR21","unstructured":"J.A. Perez-Molina, F. Pulido, S. Di Gianbenedetto, et al. Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted protease inhibitor plus lamivudine for maintenance of virological suppression Gesida study 9717. EACS - 16th European AIDS Conference, 25\u201327 October 2017, Milan, Italy. Abstract PS1\/1."},{"issue":"10123","key":"3666_CR22","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","volume":"391","author":"JM Llibre","year":"2018","unstructured":"Llibre JM, Hung C, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391(10123):839\u201349.","journal-title":"Lancet"},{"key":"3666_CR23","doi-asserted-by":"crossref","unstructured":"Taiwo BO, Marconi VC, Berzins B, et al. Dolutegravir plus lamivudine maintain HIV-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis. 2017;26 [Epub ahead of print].","DOI":"10.1093\/cid\/cix1131"},{"key":"3666_CR24","doi-asserted-by":"crossref","unstructured":"Rossetti B, Montagnani F, De Luca A. Current and emerging two-drug approaches for HIV-1 therapy in ART-na\u00efve and ART-experienced, virologically suppressed patients. Expert Opin Pharmacother 2018 Apr 20:1\u201326.","DOI":"10.1080\/14656566.2018.1457648"},{"issue":"8","key":"3666_CR25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1080\/14740338.2017.1343300","volume":"16","author":"V Soriano","year":"2017","unstructured":"Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. Expert Opin Drug Saf. 2017 Aug;16(8):923\u201332.","journal-title":"Expert Opin Drug Saf"},{"key":"3666_CR26","doi-asserted-by":"crossref","unstructured":"Bagnis CI, Stellbrink HJ. Protease inhibitors and renal function in patients with HIV infection: a systematic review. Infect Dis Ther. 2015;4(1):15\u201350.","DOI":"10.1007\/s40121-014-0056-4"},{"key":"3666_CR27","doi-asserted-by":"crossref","unstructured":"Shah BM, Schafer JJ, Desimone JA, Jr. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Pharmacotherapy 2014, 34(5):506\u2013520.","DOI":"10.1002\/phar.1386"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3666-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:06:50Z","timestamp":1579219610000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3666-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3666"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3666-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"13 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study received approval by the \u201cFondazione Policlinico Gemelli\u201d Ethics Committee (protocol number: 10978\/15), and every patient signed an informed consent before data collection.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB reports non-financial support from Bristol Myers Squibb, personal fees from Gilead Sciences, non-financial support from ViiV Healthcare, outside the submitted work. RG reports travel grants from Gilead and from Janssen-Cilag, outside the submitted work. FM reports non-financial support from Angelini, and a contract research from Novartis Vaccine and Diagnostics S.r.l., outside the submitted work. EV reports personal fees from Merck Sharp and Dohme. ADL reports grants and personal fees from Gilead, personal fees from Bristol-Myers Squibb, grants and personal fees from ViiV, personal fees from Abbvie, personal fees from Janssen, grants and personal fees from Merck Sharp and Dohme, outside the submitted work. ADL also declares to be member of the editorial board (Associate Editor) of BMC Infectious Diseases. SDG reports personal fees from Bristol-Myers Squibb, personal fees from Gilead Sciences, personal fees from Boehringer Ingelheim, personal fees from Janssen-Cilag, personal fees from GlaxoSmithKline, outside the submitted work. All other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"59"}}